RARE fundamentals
An in-depth look to ULTRAGENYX PHARMACEUTICAL INC operating, investing, and financing activities
RARE free cash flow for Q1 24 is -3.21 B MXN. For 2023, RARE free cash flow was -8.82 B MXN and operating cash flow was -8.06 B MXN.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: MXN
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM